Avantor (AVTR) Extends HIV Prevention Partnership, Is The Upside Already Priced In?

Why Avantor’s HIV prevention work is back in focus

Avantor (AVTR) is drawing attention after extending its NuSil collaboration with the Population Council on a three month dapivirine vaginal ring for HIV prevention, as the company heads into an earnings update.

This project uses NuSil’s high purity medical grade silicones and builds on the one month ring that already has approvals in several sub Saharan African countries. Investors are watching how this longer duration ring, now under European regulatory review, might influence sentiment toward Avantor’s broader life sciences portfolio.

See our latest analysis for Avantor.

The NuSil HIV prevention work has become a fresh talking point for Avantor just as the stock’s recent momentum stands in contrast to a weaker longer term record. The 90 day share price return of 58.22% and 30 day share price return of 20.82% sit against a 1 year total shareholder return that declined 11.35% and a 5 year total shareholder return that declined 67.14%.

If this kind of turnaround story has your attention, it can also be useful to see which other life sciences and medtech players are gaining traction. You can start with 40 healthcare AI stocks.

After a 58.22% move in 90 days, investors in Avantor now have to weigh how much of the story is already in the price and how much potential upside the current valuation still leaves on the table.

Most Popular Narrative: 20.4% Overvalued

Avantor’s most followed valuation narrative puts fair value at $10.31, which sits below the last close at $12.42 and frames the recent share price rebound in a different light.

The analysts have a consensus price target of $10.31 for Avantor based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $19.0, and the most bearish reporting a price target of just $7.0.

Read the complete narrative. Read the complete narrative.

The valuation hinges on a detailed earnings rebuild, a margin swing from current losses, and a future profit multiple below many life sciences peers. Investors may be curious which specific revenue and profit paths would need to align for Avantor to reach that $10.31 fair value.

Result: Fair Value of $10.31 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Avantor still faces pressure from aggressive pricing in lab solutions and flat bioprocessing revenue, which could keep margins and cash generation under strain.

Find out about the key risks to this Avantor narrative.

Another View on Avantor’s Valuation

While the analyst narrative pegs Avantor as 20.4% overvalued against a $10.31 fair value, Simply Wall St’s DCF model points in the opposite direction. On this view, Avantor at $12.42 trades below an estimated future cash flow value of $15.86. This raises a different question for investors: Is the cash flow story too optimistic or are the analyst multiples too cautious?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

If the mixed signals on Avantor have you undecided, it makes sense to move quickly and test the data yourself before sentiment shifts again. Take a closer look at the 3 key rewards and 1 important warning sign by reviewing the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Avantor?

If Avantor has sparked your interest, do not stop there. Broader idea generation can help you spot different risk and return profiles that might fit your goals.

• Target potential bargains by checking companies that screen as high quality and attractively priced through the 49 high quality undervalued stocks.
• Strengthen your focus on balance sheet resilience by reviewing the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for lesser known opportunities with solid fundamentals by using the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com